The Statin Risk Reduction Calculator

This tool runs locally in your browser.

Your personal and physiological data (including LDL-C and PREVENT Risk Score) is never transmitted, stored, or tracked.

Sovereign Health: True Statin Benefit

N-of-1 Benefit Auditor

Expected LDL-C Reduction: 30.8%
0.78%
Absolute Risk Reduction
129
Number Needed to Treat
Saved by statin: Would have had an event, but medication prevented it.
Event occurs anyway: Have a heart attack/stroke despite taking medication.
No event anyway: Never going to have an event; medication provided no clinical benefit.

Expected Absolute LDL-C Reduction by Statin

Where the Math Comes From

This calculator applies the medical establishment’s equations, specifically the CTT Collaborators’ estimate of relative risk reduction.

Reference 1: The CTT acknowledged that statin efficacy is not based on the “intensity” label of the drug, but linearly on how much the drug actually lowers your absolute LDL-C.
Reference 2: This 2022 paper confirms the CTT’s claim, saying that “A key finding has been that relative risk reduction (RRR) of CVD from statin therapy is near constant at ≈22% per 1.0 mmol/L reduction in low-density lipoprotein cholesterol (LDL-C) level over 5 years.
Reference 3: Validates the individualized benefit model: multiplying baseline predicted risk by randomized-trial relative risk reductions to yield an N-of-1 Absolute Risk Reduction
Reference 4: Presents the foundational statistical model used by the 2026 guidelines to estimate the 10-year baseline cardiovascular risk.
Reference 5: Effect sizes of different statins at different doses.

If your physician questions your numbers, direct them to the following foundational texts.

  • Reference 1: Relative Risk Reduction:(CTT Collaboration 2010):

    • Reference: Cholesterol Treatment Trialists C. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010.
  • Reference 2: Constant Relative Risk Reduction:(Kohli-Lynch et al. 2022):

    • Reference: Kohli-Lynch CN, et al. Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease. Circulation 2022

  • Reference 3: Absolute Risk Reduction Math (Thanassoulis et al., 2026):

    • Reference: Thanassoulis G, et al. Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. Circulation 2016;133:1574–81

  • Reference 4: The PREVENT Equation (Khan et al., 2024):

    • Reference: Khan SS, et al. Development and Validation of the American Heart Association’s PREVENT Equations. Circulation 2024;149:430–49

  • Reference 5: The Net Effects of Statin doses (Law et al., 2002):

    • Reference: Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423

© 2026 Dr. Lutz E. Kraushaar | Impressum | Terms | Privacy Policy | Substack

Disclaimer: This calculator is an educational and research tool. It is not a medical device. The information, analysis, and outputs provided by this software are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Do not disregard professional medical advice or delay in seeking it because of something you have read here